Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Affymax
January 08, 2014
Small cap biotechs reap rewards of the bull market in 2013
October 02, 2013
US outperformance dominates small-cap drug stock gains
July 04, 2013
Japan continues to dominate small cap risers but US biotech muscles in
April 08, 2013
Japan dominates small cap stock price rises in Q1
March 19, 2013
Affymax faces extinction after Omontys debacle
February 25, 2013
Spectre of Omontys safety concerns haunt Affymax again
January 09, 2013
Sarepta joins the big league as best-performing 2012 share
October 10, 2012
Wockardt and Arena lead small-cap gainers through nine months
July 20, 2012
Key regulatory events for the next six months in Q3 and Q4 in 2012
March 28, 2012
Affymax's fight begins as Epogen contender finally wins approval
January 20, 2012
Key regulatory events for the next six months in Q1 and Q2 2012
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
September 22, 2022
ESMO 2022 eBook
September 01, 2022
PD(L)anner – September 2022
Editor's Picks
July 27, 2022
Aids 2022 preview – Gilead shoots for an HIV cure
July 21, 2022
Private equity gets serious about drug development
July 18, 2022
Unpacking Royalty Pharma
July 19, 2022
No plain sailing for Novartis’s PD-1 plan
July 26, 2022
Move over Aduhelm, it’s tofersen’s turn
